KR101485652B1 - Material Promoting Absorption of Vitamin D and Composition Comprising the Same - Google Patents

Material Promoting Absorption of Vitamin D and Composition Comprising the Same Download PDF

Info

Publication number
KR101485652B1
KR101485652B1 KR20130007400A KR20130007400A KR101485652B1 KR 101485652 B1 KR101485652 B1 KR 101485652B1 KR 20130007400 A KR20130007400 A KR 20130007400A KR 20130007400 A KR20130007400 A KR 20130007400A KR 101485652 B1 KR101485652 B1 KR 101485652B1
Authority
KR
South Korea
Prior art keywords
mushroom
vitamin
food composition
composition according
extract
Prior art date
Application number
KR20130007400A
Other languages
Korean (ko)
Other versions
KR20140094845A (en
Inventor
임순성
이재용
박태규
최세진
이수경
장재만
Original Assignee
한림대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한림대학교 산학협력단 filed Critical 한림대학교 산학협력단
Priority to KR20130007400A priority Critical patent/KR101485652B1/en
Publication of KR20140094845A publication Critical patent/KR20140094845A/en
Application granted granted Critical
Publication of KR101485652B1 publication Critical patent/KR101485652B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명에 따른 비타민 D 섭취용 식품 조성물은 비타민 D 전구체 추출물 및 초콜릿을 포함하며, 약리적인 투여에 의해서 유발되는 부작용이 없고 비타민 D의 체내 흡수율이 우수하다.The food composition for vitamin D intake according to the present invention includes vitamin D precursor extract and chocolate, and has no adverse effect caused by pharmacological administration and has an excellent absorption rate of vitamin D in the body.

Description

비타민 D의 흡수를 촉진하는 소재 및 이를 포함하는 조성물{Material Promoting Absorption of Vitamin D and Composition Comprising the Same}BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a material for promoting absorption of vitamin D,

본 발명은 비타민 D의 흡수를 촉진하는 소재 및 이를 포함하는 조성물에 관한 것이다. 보다 구체적으로, 본 발명은 비타민 D 전구체 추출물 및 초콜릿을 포함하는 비타민 D 섭취용 식품 조성물에 관한 것이다.The present invention relates to a material for promoting absorption of vitamin D and a composition containing the same. More specifically, the present invention relates to a vitamin D precursor food composition comprising a vitamin D precursor extract and chocolate.

비타민 D는 칼슘과 인의 항상성 유지와 근골격계에 매우 중요한 호르몬(영양소)이다. 비타민 D가 충분하지 못하면 구루병, 골연화증, 골다공증뿐만 아니라 유방암, 대장암, 전립선암 등의 악성종양, 고혈압을 비롯한 심혈관 질환, 당뇨병, 다발성 경화증, 건선, 류마티스 관절염, 결핵 등도 증가한다고 보고되고 있다. Vitamin D is a very important hormone (nutrient) in the homeostasis of calcium and phosphorus and in the musculoskeletal system. If vitamin D is not enough, it is reported that not only rickets, osteoarthritis, osteoporosis but also malignant tumors such as breast cancer, colon cancer, prostate cancer, hypertension, cardiovascular diseases, diabetes mellitus, multiple sclerosis, psoriasis, rheumatoid arthritis and tuberculosis are increased.

또한, 비타민 D에는 5가지 형태(D1-D5)가 있지만 가장 널리 연구된 것은 비타민 D2와 D3이다. 비타민 D2(ergocalciferol)는 주로 식물과 무척추동물에서 합성되고, 비타민 D3(cholecalciferol)는 척추동물에서 합성되는데 두 가지 모두 보충제로도 사용되고 있다.There are also five forms of vitamin D (D 1 -D 5 ), but the most widely studied are vitamin D 2 and D 3 . Vitamin D 2 (ergocalciferol) is synthesized mainly in plants and invertebrates, and vitamin D 3 (cholecalciferol) is synthesized in vertebrates, both of which are also used as supplements.

또한, 비타민 D는 최근 인체 내 다양한 조직과 세포에서 비타민 D 수용체(vitamin D receptor, VDR)뿐 아니라 비타민 D를 활성형으로 전환하는데 필요한 1알파-수산화효소(1-hydroxylase)가 발현되는 것이 알려지면서 비타민 D 작용에 대한 새로운 조명이 이루어지고 있다. 이러한 발견은 비타민 D가 뼈나 신장, 소장 외에 다른 조직이나 기관에서 작용하거나 뼈나 무기질 항상성과 무관한 생물학적 과정에 관여하고 있을 가능성을 시사하며, 실험실연구나 역학연구결과도 이를 뒷받침하고 있다.In addition, vitamin D has recently been shown to express not only the vitamin D receptor (VDR) in various tissues and cells in the human body but also the 1-hydroxylase necessary for converting vitamin D to active form New illumination is under way for vitamin D action. This finding suggests that vitamin D may be involved in biological processes independent of bone or mineral homeostasis, acting in other tissues or organs besides the bones, kidneys, small intestine, and laboratory and epidemiological studies support this.

그러나, National Health and Nutrition Examination Survey 자료에 따르면 1988-1994년도에 비해 2001-2004 년도 미국 성인의 평균 25(OH)D 농도는 6 ng/mL가 떨어진 24 ng/mL로, 23%만이 적정수준인 30 ng/mL 이상을 유지하는 것으로 나타났고, 이전에 시행되었던 다양한 코호트 연구에서도 대상자의 52-77%가 비타민 D 부족이나 결핍에 해당하는 것으로 나타나고 있다.However, according to the National Health and Nutrition Examination Survey data, the mean 25 (OH) D concentration of US adults in 2001-2004 was 24 ng / mL, which was 6 ng / mL lower than that of 1988-1994, . In the cohort study, 52-77% of the subjects were found to have vitamin D deficiency or deficiency.

또한, 우리나라의 경우에도 골다공증을 동반한 폐경여성을 대상으로 조사한 결과에 따르면 92%가 30 ng/mL 미만에 해당하였고, 12 ng/mL 미만인 경우도 57%나 되어 이제 비타민 D 부족은 우리나라를 포함하여 전 세계적으로 심각한 건강문제가 되고 있다.Also, in Korea, 92% of patients in postmenopausal women with osteoporosis were less than 30 ng / mL, and 57% of patients in cases of less than 12 ng / mL. Vitamin D deficiency now includes Korea And is becoming a serious health problem worldwide.

이에 따라, 현재 비타민 D 부족증 치료를 위해서 약리적으로 비타민 D를 투여하는 방법이 사용되고 있다. 그러나, 약리적인 비타민 D 투여는 심각한 부작용이 나타나고 있다. 비타민 D는 지용성으로 체내 지방에 저장이 되기 때문에 비타민 D에 의한 독성 증상이 나타나면 치료를 중단한 후에도 수 주간 증상이 나타날 수 있으며, 약리적 비타민 D 투여의 가장 중요한 부작용은 장에서 칼슘과 인의 흡수 증가, 골격의 골흡수 증가에 의한 고칼슘혈증, 고인산혈증 및 고칼슘뇨증이다. 이외에도 오심을 동반한 위장관증상, 신경근육증상, 갈증 등의 부작용이 발생할 수 있다. Therefore, currently, vitamin D is pharmacologically administered to treat vitamin D deficiency. However, pharmacologic vitamin D administration presents serious side effects. Because vitamin D is stored in the body fat in fat-soluble form, toxic symptoms caused by vitamin D may cause symptoms for several weeks after discontinuation of treatment. The most important side effect of pharmacologic vitamin D administration is increased absorption of calcium and phosphorus in the intestine, Hypercalcemia, hyperphosphatemia and hypercalciuria due to increased bone resorption of the skeleton. In addition, side effects such as gastrointestinal symptoms, neuromuscular symptoms, and thirst with nausea can occur.

예를 들어, 하루에 1 μg의 칼시트리올을 1년 이상 사용한 경우 고칼슘혈증의 빈도가 증가하나 이로 인하여 치료를 중단하는 경우는 많지 않기 때문에, 치료를 계속 진행하여 고칼슘혈증이나 고칼슘뇨증이 장기간 지속되는 경우 신결석증이나 신석회화증이 발생할 수 있고 이에 의해 신장기능이 나빠질 수 있다.For example, when 1 μg of calcitriol per day is used for 1 year or more, the frequency of hypercalcemia increases, but the treatment is not stopped frequently. Therefore, if the hypercalcemia or hypercalciuria continues for a long period of time, Abdominal pain or nephrolithiasis may occur and kidney function may be deteriorated.

이처럼 약리적인 비타민 D의 투여는 심각한 부작용을 나타내므로 식품 또는 보충제로 섭취하는 것이 가장 안전하지만 현재까지 비타민 D에 관련된 연구로는 주로 대사, 생리 효과, 분석법 등에 관한 것들이 주종을 이루었다.As such, the administration of pharmacologic vitamin D has serious side effects, so it is safest to take it as a food or supplements. However, to date vitamin D studies have mainly been related to metabolism, physiological effects, and analytical methods.

본 발명의 목적은 약리적인 투여에 의해서 유발되는 부작용이 없는 비타민 D 섭취용 식품 조성물을 제공하는 것이다.It is an object of the present invention to provide a food composition for the intake of vitamin D which has no adverse effects caused by pharmacological administration.

본 발명의 다른 목적은 비타민 D의 체내 흡수율이 우수한 비타민 D 섭취용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for vitamin D intake which has an excellent absorption rate of vitamin D in the body.

본 발명에 따른 비타민 D 섭취용 식품 조성물은 비타민 D 전구체 추출물 및 초콜릿을 포함한다. 상기 비타민 D 전구체 추출물은 비타민 D 전구체(예컨대, 에르고스테롤) 또는 비타민 D를 포함하는 추출물을 의미하며, 예를 들어, 식용 식물 또는 동물로부터 유래한 추출물일 수 있다.The food composition for vitamin D according to the present invention includes a vitamin D precursor extract and chocolate. The vitamin D precursor extract means an extract containing a vitamin D precursor (e.g., ergosterol) or vitamin D, and may be, for example, an edible plant or an animal-derived extract.

본 발명의 일 구현예에서, 비타민 D 전구체 추출물은 버섯 추출물을 포함할 수 있다.In one embodiment of the invention, the vitamin D precursor extract may comprise mushroom extract.

버섯은 영양항적 측면에서 단백질, 지질, 탄수화물의 함량이 적어 에너지원으로는 가치가 적지만 비타민 B2와 나이아신이 비교적 다른 채소에 비해 많이 존재하며 특히 식물성 식품에는 거의 존재하지 않는 비타민 D의 전구체인 에르고스테롤(ergosterol)이 풍부하게 들어있다.Mushrooms are low in protein, lipid and carbohydrate content in terms of nutritional trait, but are less valuable as energy sources. Vitamin B 2 and niacin are more abundant than other vegetables, especially vitamin D precursors It is rich in ergosterol.

에르고스테롤은 자외선 조사에 의해 비타민 D2(ergocalsiferol)와 비타민 D3(cholecalciferol)로 전환되며 신장에서 비타민 D의 활성형인 1,25-디하이드록시비타민 D로 전환되어 소장에서 칼슘결합-단백질의 합성을 촉진시켜 칼슘의 흡수를 돕는 중요한 역할을 한다. Ergosterol is converted to vitamin D 2 (ergocalsiferol) and vitamin D 3 (cholecalciferol) by ultraviolet irradiation and is converted to 1,25-dihydroxy vitamin D, the active form of vitamin D in the kidney, To promote the absorption of calcium plays an important role.

주요 버섯의 수분함유량, 비타민 D2와 D3 함량은 다음 표 1과 같다.The moisture content, vitamin D 2 and D 3 content of the main mushroom are shown in Table 1 below.

[표 1] [Table 1]

(μg/식용 부분 100g)                                             (μg / 100g edible portion)

Figure 112013006559913-pat00001
Figure 112013006559913-pat00001

(비타민 D의 함량 = 비타민 D2의 함량 + 비타민 D3의 함량)(Content of vitamin D = content of vitamin D 2 + content of vitamin D 3 )

본 발명의 일 구현예에서, 버섯은 표고버섯, 느타리버섯, 팽이버섯, 양송이버섯, 목이버섯, 석이버섯, 운지버섯, 영지버섯 및 이들의 혼합물로 이루어지는 군으로부터 선택될 수 있다.In one embodiment of the invention, the mushroom may be selected from the group consisting of shiitake mushroom, oyster mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, fenugreek mushroom, gentian mushroom and mixtures thereof.

본 발명의 일 구현예에서, 버섯은 표고버섯일 수 있다.In one embodiment of the invention, the mushroom may be a shiitake mushroom.

본 발명의 일 구현예에서, 버섯은 자외선 조사 하에서 건조한 버섯일 수 있다.In one embodiment of the present invention, the mushroom may be a dried mushroom under ultraviolet irradiation.

본 발명의 일 구현예에서, 버섯은 0 내지 60 ℃에서 1시간 내지 1주일 동안 건조한 버섯일 수 있다.In one embodiment of the present invention, the mushroom may be a mushroom which has been dried at 0 to 60 < 0 > C for 1 hour to 1 week.

본 발명의 일 구현예에서, 건조한 버섯의 수분 함유량은 0 내지 15 중량%일 수 있다.In one embodiment of the present invention, the moisture content of the dried mushroom may be 0 to 15% by weight.

본 발명의 일 구현예에서, 버섯 추출물은 버섯을 유기 용매로 추출한 것일 수 있다.In one embodiment of the present invention, the mushroom extract may be an organic solvent extracted mushroom.

본 발명의 일 구현예에서, 유기 용매는 페녹시에탄올, 프로필파라벤, 옥시페놀, 벤조페논 및 에탄올로 이루어지는 군으로부터 선택될 수 있다.In one embodiment of the invention, the organic solvent may be selected from the group consisting of phenoxyethanol, propylparaben, oxyphenol, benzophenone and ethanol.

본 발명의 일 구현예에서, 버섯 추출물은 버섯을 유기 용매로 50 내지 100 ℃에서 1 내지 10시간 동안 환류 냉각 추출한 것일 수 있다.In one embodiment of the present invention, the mushroom extract may be obtained by subjecting the mushroom to an organic solvent under reflux and cooling at 50 to 100 DEG C for 1 to 10 hours.

본 발명의 일 구현예에서, 초콜릿은 카카오매스를 포함하고, 코코아버터, 우유, 버터, 설탕, 향료 또는 이들의 혼합물을 추가로 포함할 수 있다.In one embodiment of the invention, the chocolate comprises cocoa mass and may further comprise cocoa butter, milk, butter, sugar, flavoring or a mixture thereof.

본 발명의 일 구현예에서, 식품 조성물은 향미제, 풍미제, 착색제, 충진제, 안정화제, 천연 탄수화물, 영양제, 비타민제, 증점제, pH 조절제, 방부제 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 첨가제를 추가로 포함할 수 있다. In one embodiment of the invention, the food composition further comprises additives selected from the group consisting of flavors, flavors, colorants, fillers, stabilizers, natural carbohydrates, nutrients, vitamins, thickeners, pH adjusting agents, preservatives and mixtures thereof As shown in FIG.

본 발명에 따른 비타민 D 섭취용 식품 조성물은 약리적인 투여에 의해서 유발되는 부작용이 없고 비타민 D의 체내 흡수율이 우수하다.The food composition for vitamin D intake according to the present invention has no side effects caused by pharmacological administration and has an excellent absorption rate of vitamin D in the body.

이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited by the following examples.

실시예Example

제조예Manufacturing example 1 One

건조된 표고버섯 100g을 분말화(20-30mesh)한 후 95% 주정 2L를 가하여 80℃에서 3시간 동안 환류 냉각 추출한 후 여과하여 여액과 잔사를 얻었고, 이 잔사를 동일한 방법으로 2회 반복하여 추출/여과하였다. 추출물을 Whatman No. 2 여과지로 여과하여 잔사를 제거하고 감압농축한 후 동결 건조하여 15g(15%)의 표고버섯 추출물을 제조하였다. 100 g of dried mushroom was pulverized (20-30 mesh), 2 L of 95% alcohol was added, and the mixture was refluxed for 3 hours at 80 ° C. The mixture was filtered to obtain a filtrate and a residue. / Filtered. The extract was extracted with Whatman No. 2 filter paper to remove the residue, concentrated under reduced pressure, and lyophilized to prepare 15 g (15%) of mushroom extract.

실시예Example 1 및  1 and 비교예Comparative Example 1-5 1-5

하기 표 2에 기재된 바대로 구성성분들을 혼합하여 식품 조성물을 제조하였다(함량단위 g).Food compositions were prepared by mixing the ingredients as set forth in Table 2 below (content unit g).

[표 2][Table 2]

Figure 112013006559913-pat00002
Figure 112013006559913-pat00002

실험예 1-비타민 DExperimental Example 1 - Vitamin D 33 흡수율 평가 Absorption rate evaluation

4주령의 수컷 Sprague-Dawley (SD) rat을 (주)중앙실험동물에서 구입하여 사용하였으며, 실험식이 시작 전 일주일간 일반배합사료(Purina Co., Seoul, korea)로 예비 사육하였다. 실험 그룹을 각 그룹 당 5마리씩 난괴법(completely randomize design)에 의해 표고버섯 추출물과 초콜릿 혼합 급여군(실시예 1), 정상 식이 대조군(비교예 1), 표고버섯 추출물 급여군(비교예 2), 초콜릿 급여군(비교예 3), 비타민 D3 급여군(비교예 4), 비타민 D3와 초콜릿 혼합 급여군(비교예 5)으로 총 6군으로 나누어, 제조한 식품 조성물을 식사 1 kg당 1g의 함량으로 2주간 사육하였다. 식이구성은 표 2과 같고, 식이 및 식수는 자유섭취하게 하였다. 사육 조건은 온도 20±2℃, 습도 50±10%로 하였으며, 어두운 조명주기(dark-light cycle)는 12시간을 주기로 자동 조절되게 하였다. Four-week-old male Sprague-Dawley (SD) rats were purchased from Central laboratory animals and pre-fed with normal compound feed (Purina Co., Seoul, Korea) for one week before the experiment. The experimental group was divided into two groups: a sham mushroom extract and a chocolate mixed food group (Example 1), a normal diet control group (Comparative Example 1), and a shiitake mushroom extract feeding group (Comparative Example 2) , The chocolate-fed group (Comparative Example 3), the vitamin D 3- fed group (Comparative Example 4), and the vitamin D 3 and chocolate mixed feed group (Comparative Example 5) 1g. The composition of the diets was as shown in Table 2, and diets and drinking water were free. The incubation conditions were 20 ± 2 ℃ for temperature and 50 ± 10% for humidity. The dark-light cycle was automatically controlled for 12 hours.

사육기간이 완료된 후, 12시간 절식 후 마취시킨 후 혈액을 채취하여 3000 rpm, 4℃에서 15분간 원심 분리하여 혈청을 분리하였다. 분리된 혈청은 분석하기 전까지 -80℃에서 보관하였으며, 분석 전 혈청에 헥산을 가하여 비타민 D3를 추출하여 HPLC를 이용하여 비타민 D3 함량을 분석하였다. HPLC를 이용한 비타민 D3함량 분석에서 칼럼은 YMC C18 (250 x 4.6 mm, 4 μm), 이동상은 메탄올과 물을 사용했으며, 유속은 0.8 mL/min, 시료 주입량은 20 μL, 검출기 파장은 280 nm에서 분석하였으며, 그 결과를 표 3에 나타내었다. After the breeding period was completed, the animals were anesthetized after fasting for 12 hours. Blood was collected and the serum was separated by centrifugation at 3000 rpm and 4 ° C for 15 minutes. Separated serum was stored at -80 ° C until analysis. Vitamin D 3 was extracted by adding hexane to the serum before analysis, and the content of vitamin D 3 was analyzed by HPLC. In the analysis of vitamin D 3 content by HPLC, YMC C18 (250 x 4.6 mm, 4 μm) was used as the column, methanol and water were used as the mobile phase, the flow rate was 0.8 mL / min, the sample injection amount was 20 μL, And the results are shown in Table 3.

[표 3][Table 3]

Figure 112013006559913-pat00003
Figure 112013006559913-pat00003

상기 표 3을 보면, 표고버섯 추출물 및 초콜릿을 포함하는 식품 조성물을 사용한 실시예 1은 포고버섯 추출물 및 초콜릿을 포함하지 않은 비교예 1, 표고버섯 추출물만을 포함한 비교예 2, 표고버섯 추출물 대신에 초콜릿을 포함한 비교예 3에 비해, 비타민 D3의 체내 흡수율이 현저히 우수함을 알 수 있다. In Table 3, Example 1 using a food composition containing mushroom extract and chocolate showed that Comparative Example 1, which did not contain mushroom extract and chocolate, Comparative Example 2, which contained only mushroom extract, , The absorption rate of vitamin D 3 in the body was remarkably superior to that of Comparative Example 3,

또한, 실시예 1과 비교예 2, 또는 비교예 4와 5를 서로 비교해 보면, 초콜릿은 비타민을 함유한 성분과 조합됨에 따라 비타민 D3의 체내 흡수율을 현저히 증가시켜주는 시너지 효과를 나타냄을 알 수 있다.Further, when comparing Example 1 with Comparative Example 2 or Comparative Examples 4 and 5, it can be seen that the chocolate exhibits a synergistic effect that significantly increases the absorption rate of vitamin D 3 in the body as it is combined with a vitamin-containing ingredient have.

또한, 표고버섯 추출물 및 초콜릿을 포함하는 식품 조성물을 사용한 실시예 1은, 표 1에 기재된 표고버섯 내의 비타민 D3의 함량과 동일한 함량의 비타민 D3 및 초콜릿을 포함하는 식품 조성물을 사용한 비교예 5에 비해, 비타민 D3의 체내 흡수율이 우수함을 알 수 있으며, 천연물에서 유래한 소재를 사용하여 약리적인 투여에 의해서 유발되는 부작용이 현저히 감소될 것으로 예상된다.Example 1 using a food composition containing mushroom extract and chocolate also showed that vitamin D 3 in the same amount as the content of vitamin D 3 in the mushroom described in Table 1 and Comparative Example 5 using a food composition containing chocolate , Vitamin D 3 is superior to vitamin D 3 , and it is expected that the side effects caused by pharmacological administration will be remarkably reduced by using materials derived from natural products.

Claims (12)

버섯 추출물 및 초콜릿을 포함하는 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.
A food composition for increasing the in-vivo absorption of vitamin D, including mushroom extract and chocolate.
삭제delete 제1항에 있어서, 버섯이 표고버섯, 느타리버섯, 팽이버섯, 양송이버섯, 목이버섯, 석이버섯, 운지버섯, 영지버섯 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The method according to claim 1, wherein the mushroom is selected from the group consisting of shiitake mushroom, oyster mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, mushroom mushroom, Food composition. 제3항에 있어서, 버섯이 표고버섯인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The food composition according to claim 3, wherein the mushroom is a shiitake mushroom. 제1항에 있어서, 버섯이 자외선 조사 하에서 건조한 버섯인 식품 조성물.The food composition according to claim 1, wherein the mushroom is dried mushroom under ultraviolet irradiation. 제5항에 있어서, 버섯이 0 내지 60 ℃에서 1시간 내지 1주일 동안 건조한 버섯인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.6. The food composition according to claim 5, wherein the mushroom is a mushroom dried at 0 to 60 DEG C for 1 hour to 1 week. 제5항에 있어서, 상기 건조한 버섯의 수분 함유량이 0 내지 15 중량%인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.6. The food composition according to claim 5, wherein the dry mushroom has a water content of 0 to 15% by weight. 제1항에 있어서, 상기 버섯 추출물이 버섯을 유기 용매로 추출한 것인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The food composition according to claim 1, wherein the mushroom extract is an organic solvent-extracted mushroom. 제8항에 있어서, 상기 유기 용매가 페녹시에탄올, 프로필파라벤, 옥시페놀, 벤조페논 및 에탄올로 이루어지는 군으로부터 선택되는 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The food composition according to claim 8, wherein the organic solvent is selected from the group consisting of phenoxyethanol, propylparaben, oxyphenol, benzophenone and ethanol. 제8항에 있어서, 상기 버섯 추출물이 버섯을 유기 용매로 50 내지 100 ℃에서 1 내지 10시간 동안 환류 냉각 추출한 것인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.9. The food composition according to claim 8, wherein the mushroom extract is reflux-cooled and extracted with mushroom as an organic solvent at 50 to 100 DEG C for 1 to 10 hours. 제1항에 있어서, 상기 초콜릿이 카카오매스를 포함하고, 코코아버터, 우유, 버터, 설탕, 향료 또는 이들의 혼합물을 추가로 포함하는 것인 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The food composition of claim 1, wherein the chocolate comprises cocoa mass and further comprises cocoa butter, milk, butter, sugar, flavoring or a mixture thereof. 제1항에 있어서, 향미제, 풍미제, 착색제, 충진제, 안정화제, 천연 탄수화물, 영양제, 비타민제, 증점제, pH 조절제, 방부제 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 첨가제를 추가로 포함하는 비타민 D의 체내 흡수율을 증가시키기 위한 식품 조성물.The composition according to claim 1, further comprising an additive selected from the group consisting of flavors, flavors, colorants, fillers, stabilizers, natural carbohydrates, nutrients, vitamins, thickeners, pH adjusters, preservatives and mixtures thereof. Of the total amount of the composition.
KR20130007400A 2013-01-23 2013-01-23 Material Promoting Absorption of Vitamin D and Composition Comprising the Same KR101485652B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR20130007400A KR101485652B1 (en) 2013-01-23 2013-01-23 Material Promoting Absorption of Vitamin D and Composition Comprising the Same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130007400A KR101485652B1 (en) 2013-01-23 2013-01-23 Material Promoting Absorption of Vitamin D and Composition Comprising the Same

Publications (2)

Publication Number Publication Date
KR20140094845A KR20140094845A (en) 2014-07-31
KR101485652B1 true KR101485652B1 (en) 2015-01-23

Family

ID=51740350

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20130007400A KR101485652B1 (en) 2013-01-23 2013-01-23 Material Promoting Absorption of Vitamin D and Composition Comprising the Same

Country Status (1)

Country Link
KR (1) KR101485652B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236400B1 (en) 2020-06-30 2021-04-05 이영환 A vitamin compound containing nitric oxide precursors
KR102681451B1 (en) 2021-11-10 2024-07-03 오호영 Method for manufacturing mushroom crunchy chocolate using tree ear mushroom and tree ear mushroom crunchy chocolate manufactured by the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101663143B1 (en) * 2014-10-22 2016-10-06 재단법인 장흥군버섯산업연구원 Method for obtaining vitamin D2 from shiitake
RU2579212C1 (en) * 2015-01-19 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) Composition for producing chocolate
KR102604237B1 (en) * 2016-06-02 2023-11-20 (주)아모레퍼시픽 Composition for enhancing the bioavailability of fat-soluble vitamins
KR102172788B1 (en) * 2018-11-26 2020-11-02 전라북도(농업기술원) Health functional food for supplementing vitamin D2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070083515A (en) * 2004-07-29 2007-08-24 에베레트 래보러토리즈, 인크. Compositions and methods for nutrition supplementation
KR20070121275A (en) * 2006-06-21 2007-12-27 윤여강 Functional gum containing ergosterol-like structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070083515A (en) * 2004-07-29 2007-08-24 에베레트 래보러토리즈, 인크. Compositions and methods for nutrition supplementation
KR20070121275A (en) * 2006-06-21 2007-12-27 윤여강 Functional gum containing ergosterol-like structure

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236400B1 (en) 2020-06-30 2021-04-05 이영환 A vitamin compound containing nitric oxide precursors
KR102681451B1 (en) 2021-11-10 2024-07-03 오호영 Method for manufacturing mushroom crunchy chocolate using tree ear mushroom and tree ear mushroom crunchy chocolate manufactured by the same

Also Published As

Publication number Publication date
KR20140094845A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
KR101485652B1 (en) Material Promoting Absorption of Vitamin D and Composition Comprising the Same
US9446088B2 (en) Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25 dihydroxyvitamin D3 glycosides and quercetin glycosides
KR19990036207A (en) Lipid metabolism improver
KR20080108523A (en) Fat accumulation inhibitor
Kim et al. Okara, a soybean by-product, prevents high fat diet-induced obesity and improves serum lipid profiles in C57BL/6J mice
El-Sheikh et al. Effect of moringa leaves on lipid content of table eggs in layer hens
KR100703180B1 (en) A pharmaceutical composition comprising the extract of herb mixture for treating or preventing osteoporosis disease
CN105581331B (en) A kind of nutritional composition for calcium supplement
EP3666269A1 (en) Blood flow improver
JP2004000171A (en) Functional food product containing maca
KR20190017704A (en) Composition for stimulation of bone formation comprising Curcuma xanthorrhiza extract or xanthorrhizol as effective component
KR101852442B1 (en) Composition containing ginseng berry extract for preventing or improving bone disease
AU2010309857A1 (en) Use of extracts from Salonum glaucophyllum for treating bone metabolism disorders and kidney disorders
WO2005079602A1 (en) Food supplement composition and use thereof
JP5264269B2 (en) Sex hormone inducer and protein metabolism improvement and constitution improvement method using the same
KR101636612B1 (en) Composition comprising the extract of Rubus coreanus Miquel and Astragalus membranaceus Bunge for preventing and treating of osteoporosis and bone disease
US8124137B2 (en) Composition for prevention and/or treatment of tumors containing acacia bark derivative
WO2015029968A1 (en) Clock gene expression level modifier
KR20160133241A (en) A composition comprising the extract of Artemisia capillaris Thunb and the compound extracted therefrom for preventing and treatment of bone disease
CN103316021B (en) The pharmaceutical composition of a kind of calcitriol and calcic thing composition and purposes
TWI691334B (en) Internally taken compositions, preparations, and uses
EP3697427A2 (en) Compositions for improving lean body mass, brown adipose tissue and for inhibiting advanced glycation end products
CN116474076A (en) Composition and preparation for preventing and treating sarcopenia
IT202000021907A1 (en) Composition‌ ‌nutraceutical‌ ‌multipurpose‌
KR20100081116A (en) A composition having antidiabetes activity consisting of ligustrum fruit and red-ginseng cheongkukjang powder

Legal Events

Date Code Title Description
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20180108

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20200115

Year of fee payment: 6

R401 Registration of restoration